<DOC>
	<DOCNO>NCT01528306</DOCNO>
	<brief_summary>This pilot study design see HP802-247 , investigational treatment live human skin cell , help heal blister wound subject Dystrophic Epidermolysis Bullosa ( DEB ) . The durability skin heal wound treat HP802-247 also assess .</brief_summary>
	<brief_title>A Pilot Study HP802-247 Dystrophic Epidermolysis Bullosa</brief_title>
	<detailed_description />
	<mesh_term>Epidermolysis Bullosa</mesh_term>
	<mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
	<criteria>Written consent must obtain parent legally authorize representative . Assent obtain accord local requirement . Subjects clinical diagnosis DEB recur blister , ≥ 2 year age Screening . Subjects may either sex race skin type provide skin color , opinion Investigator , interfere study assessment . A parent legally authorize representative must willing able ensure subject present require study visit . A parent legally authorize representative must able follow instruction . Have open wound ≤ 72 hour : still open scabbed crust dermatologic disease and/or condition treatment area ( DEB recur blister ) , include active recent infection ( within 7 day ) may exacerbate treatment , require treatment antibiotic / antifungal /antivirals , require surgical intervention , cause difficulty examination ≥ 4 cm² ≤ 48 cm2 total area ( open portion ) Females childbearing potential ( defined postmenarcheal document medical history ) may participate study meet following condition : breast feeding ; negative urine pregnancy test Week 1 Period 1 ; agree undertake schedule urine pregnancy test Week 1 Periods 1 , 2 , &amp; 3 study exit intend become pregnant study ; use adequate birth control method agree continue use method duration study A parent legally authorize representative must willing able ensure subject present require study visit ( minor subject ) A parent legally authorize representative must able follow instruction ( minor subject ) Contraindications hypersensitivity use test article , component ( e.g. , aprotinin , fibrinogen ) , substance use manufacture test article ( e.g. , penicillin , streptomycin , amphotericin B , bovine serum albumin ) . Therapy another investigational agent within thirty ( 30 ) day Screening Visit , study . Have uncontrolled intercurrent chronic illness , opinion Investigator , would limit compliance study requirement , represent potential safety risk , require treatment excluded drug/treatment . The Investigator Medical Monitor may declare subject ineligible valid medical reason .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>HP802-247</keyword>
	<keyword>EB ( epidermolysis bullosa )</keyword>
</DOC>